Conduit and Sarborg Advance to Phase II of AI-Driven Drug Development
Conduit Pharmaceuticals (NASDAQ: CDT) announced the successful completion of Phase I in its AI-driven drug development collaboration with Sarborg Limited. With all milestones achieved, the partnership is now transitioning to Phase II, which will focus on developing personalized software dashboards to improve operational efficiency and decision-making.
Phase I, initiated in December 2024, laid the groundwork for integrating AI and cybernetics into Conduit’s drug development process. It involved aligning Sarborg’s AI-driven processes with Conduit’s portfolio needs, validating proprietary inputs, and conducting an in-depth market analysis of cocrystal candidates. The phase also established key algorithmic approaches aimed at optimizing drug repurposing, discovery, and clinical trial monitoring.
The transition to Phase II marks a strategic shift toward technological infrastructure development. Conduit and Sarborg will create AI-powered dashboards to provide real-time insights into clinical trials, drug discovery, and portfolio management. These tools are expected to enhance agility in decision-making and improve operational oversight, particularly in advancing treatments for autoimmune disorders.
With this next phase, Conduit continues its commitment to leveraging AI for innovation in drug development, aiming to optimize efficiency and accelerate the path to new therapies.
You might like this article: Celly Nutrition Secures Investment Bank Partner to Fuel Growth and IPO Plans
